AVEO Pharmaceuticals   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Cambridge Massachusetts United States (2003)

Organization Overview

First Clinical Trial
2006
NCT00381654
First Marketed Drug
2021
tivozanib (Fotivda)
First NDA Approval
2021
tivozanib (Fotivda)
Last Known Activity
2024

Timeline

NOW
  • Now

Alternative names

Aveo Oncology Pharmaceuticals | AVEO Pharmaceuticals, Inc. | AVEO PHARMS

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 2)

Carcinoma (Phase 3)

Carcinoma, Hepatocellular (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Renal Cell (Phase 3)

Carcinoma, Squamous Cell (Phase 1)

Colorectal Neoplasms (Phase 2)

Fallopian Tube Neoplasms (Phase 2)

Gastrointestinal Neoplasms (Phase 2)

Leukemia (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Liver Diseases (Phase 1)

Liver Neoplasms (Phase 2)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 1)

Multiple Myeloma (Phase 1)

Neoplasm Metastasis (Phase 1)

Neoplasms (Phase 2)

Neoplasms, Plasma Cell (Phase 1)

Neoplasms, Second Primary (Phase 1)

Ovarian Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 1)

Respiratory Tract Neoplasms (Phase 2)

Sarcoma (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 1)

Triple Negative Breast Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 46
  • # of Trial APIs: 24